The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1b study of the anti-cancer stem cell agent demcizumab (DEM), pemetrexed (PEM) & carboplatin (CARBO) in patients (pts)with 1st line non-squamous NSCLC.
 
Mark James McKeage
No Relationships to Disclose
 
Brett Gordon Maxwell Hughes
No Relationships to Disclose
 
Ben Markman
No Relationships to Disclose
 
Manuel Hidalgo
No Relationships to Disclose
 
Michael Millward
No Relationships to Disclose
 
Michael B. Jameson
No Relationships to Disclose
 
Dean Laurence Harris
No Relationships to Disclose
 
Robert J. Stagg
Employment - OncoMed
Leadership - OncoMed
Stock and Other Ownership Interests - OncoMed
Patents, Royalties, Other Intellectual Property - OncoMed
 
Ann M. Kapoun
Employment - OncoMed
Leadership - OncoMed
Stock and Other Ownership Interests - OncoMed
Patents, Royalties, Other Intellectual Property - co-author of patents filed at OncoMed (Inst)
Travel, Accommodations, Expenses - OncoMed
 
Eric Holmgren
Employment - OncoMed
Stock and Other Ownership Interests - OncoMed
 
Jakob Dupont
Employment - OncoMed
Leadership - OncoMed
Stock and Other Ownership Interests - OncoMed
Patents, Royalties, Other Intellectual Property - OncoMed
 
Dusan Kotasek
No Relationships to Disclose